[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 319, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1968759, "exercisedValue": 0, "unexercisedValue": 5090000}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 670578, "exercisedValue": 0, "unexercisedValue": 3031375}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 30.73, "open": 30.65, "dayLow": 30.37, "dayHigh": 31.0, "regularMarketPreviousClose": 30.73, "regularMarketOpen": 30.65, "regularMarketDayLow": 30.37, "regularMarketDayHigh": 31.0, "beta": 2.26, "forwardPE": 34.71351, "volume": 1136356, "regularMarketVolume": 1136356, "averageVolume": 2248961, "averageVolume10days": 1424670, "averageDailyVolume10Day": 1424670, "bid": 26.26, "ask": 35.13, "bidSize": 100, "askSize": 100, "marketCap": 4780471808, "fiftyTwoWeekLow": 12.84, "fiftyTwoWeekHigh": 36.84, "priceToSalesTrailing12Months": 18.053823, "fiftyDayAverage": 31.4378, "twoHundredDayAverage": 24.323376, "currency": "USD", "enterpriseValue": 4320245760, "profitMargins": -0.054250002, "floatShares": 132762562, "sharesOutstanding": 155664992, "sharesShort": 26879160, "sharesShortPriorMonth": 25989480, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1727, "heldPercentInsiders": 0.098129995, "heldPercentInstitutions": 0.63707, "shortRatio": 10.16, "shortPercentOfFloat": 0.1908, "impliedSharesOutstanding": 155767008, "bookValue": 1.338, "priceToBook": 22.952166, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.966, "netIncomeToCommon": -14364000, "trailingEps": -0.1, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 16.316, "enterpriseToEbitda": -10588.838, "52WeekChange": 1.3212397, "SandP52WeekChange": 0.22894537, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TGTX", "underlyingSymbol": "TGTX", "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "firstTradeDateEpochUtc": 1272893400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d6673518-e04c-3ac1-8be7-75085ffff3ed", "messageBoardId": "finmb_143627354", "gmtOffSetMilliseconds": -18000000, "currentPrice": 30.71, "targetHighPrice": 55.0, "targetLowPrice": 10.0, "targetMeanPrice": 40.33333, "targetMedianPrice": 44.5, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 341040992, "totalCashPerShare": 2.376, "ebitda": -408000, "totalDebt": 253808000, "quickRatio": 3.651, "currentRatio": 4.588, "totalRevenue": 264790000, "debtToEquity": 132.084, "revenuePerShare": 1.829, "returnOnAssets": -0.00068999996, "returnOnEquity": -0.08049, "grossProfits": 233848992, "freeCashflow": -45062376, "operatingCashflow": -28086000, "earningsGrowth": -0.973, "revenueGrowth": -0.494, "grossMargins": 0.88315004, "ebitdaMargins": -0.00154, "operatingMargins": 0.14824, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]